Latest / Cyrona Cell Podcast: Stem Cell Therapy in Malaysia / Stem Cell Therapy for Cerebral Palsy: How Rehab Fits In
Transcript
- 0:00SPEAKER_02: Welcome to the Sino Cell Podcast.
- 0:02SPEAKER_00: Thanks for having me back.
- 0:03SPEAKER_02: So if a child suffers a brain injury, I think common sense usually dictates that um the damage is done.
- 0:09SPEAKER_02: You know, the event is over.
- 0:11SPEAKER_00: That is the assumption, yes.
- 0:12SPEAKER_02: But because a child's body is constantly growing, a static brain injury actually creates a constantly moving, evolving target for their developing muscles and bones.
- 0:22SPEAKER_02: So today, we are bringing you a deep dive into the clinical data surrounding an experimental treatment for cerebral palsy.
- 0:28SPEAKER_00: Aaron Powell Which is a incredibly complex topic.
- 0:30SPEAKER_02: Aaron Powell It really is.
- 0:31SPEAKER_02: We've gathered a stack of recent clinical articles, data reviews, and trial reports to figure out how this experimental approach fits alongside standard care.
- 0:40SPEAKER_02: Because our mission here is to extract the actual science for you.
- 0:44SPEAKER_02: We want to look closely at what the trials measured, what they reported, and frankly, what is still completely unknown.
- 0:50SPEAKER_00: Aaron Powell And establishing a grounded evidence-based baseline is really the only way to approach this data.
- 0:56SPEAKER_00: The treatments we're going to explore today are strictly experimental.
- 0:59SPEAKER_02: Aaron Powell So they are not standard care.
- 1:01SPEAKER_00: No, they are not established standard care.
- 1:03SPEAKER_00: We are looking solely at what the published data suggests.
- 1:06SPEAKER_00: We aren't making any promises.
- 1:08SPEAKER_00: We are certainly not suggesting a cure, and we aren't offering personal medical advice.
- 1:12SPEAKER_02: Just sticking to the text.
- 1:13SPEAKER_00: Aaron Ross Powell Because when looking at stem cell research in this field, the clinical language we use carries massive weight.
- 1:19SPEAKER_00: You will hear us rely on terms like reported or may or small average gains.
- 1:24SPEAKER_00: That careful phrasing accurately reflects the very young, highly complex state of this science.
- 1:30SPEAKER_02: Aaron Powell Okay, let's unpack this for a moment.
- 1:33SPEAKER_02: I was reading through the 2020 clinical review we pull for this deep dive, and it completely shifted my perspective on what cerebral palsy actually entails.
- 1:42SPEAKER_00: Aaron Powell In what way?
- 1:43SPEAKER_02: Well, the literature defines it as a group of lifelong conditions affecting movement, muscle tone, and coordination.
- 1:51SPEAKER_02: And that 2020 review actually identified it as the most common physical disability of childhood.
- 1:58SPEAKER_02: But the defining characteristic that stood out to me, I saw this in a 2021 trial report, is that the underlying brain injury itself, which happens before or just after birth, does not progress.
- 2:11SPEAKER_00: That is a crucial distinction.
- 2:12SPEAKER_00: The neurological injury is a singular static event.
- 2:17SPEAKER_02: So if the injury is static, why is the resulting condition considered a lifelong evolving challenge?
- 2:23SPEAKER_00: Aaron Ross Powell Because the neurological baseline is static, but human biology is entirely dynamic.
- 2:29SPEAKER_00: I mean, think about a child's physical development.
- 2:31SPEAKER_02: Aaron Powell They are constantly growing.
- 2:32SPEAKER_00: Constantly.
- 2:33SPEAKER_00: As they age, their bones lengthen, their mass increases, and they are subjected to gravity in completely new ways as they attempt to sit up or stand.
- 2:42SPEAKER_02: So the mechanics change?
- 2:43SPEAKER_00: Yes.
- 2:44SPEAKER_00: The physical challenges unfold because the body is forced to develop around that initial brain injury.
- 2:49SPEAKER_00: That injury disrupts how signals are sent from the brain down to the muscles.
- 2:54SPEAKER_02: So the signals are misfiring.
- 2:55SPEAKER_00: They misfire.
- 2:56SPEAKER_00: And this creates altered mechanical forces.
- 2:59SPEAKER_00: So imagine a bone growing longer.
- 3:01SPEAKER_00: A muscle that is receiving abnormal signals might become tight, and it might fail to stretch along with that growing bone.
- 3:08SPEAKER_02: Oh, I see.
- 3:09SPEAKER_00: Over time, that constant tension can lead to joint stiffness or even permanent skeletal changes.
- 3:15SPEAKER_02: So the brain injury hasn't worsened by a single millimeter.
- 3:18SPEAKER_00: Not at all.
- 3:19SPEAKER_00: But the physical reality of living in a growing body with those altered signals creates relentless daily challenges.
- 3:25SPEAKER_02: That paints a very clear picture of why standard care requires constant ongoing management, which naturally leads us into why researchers are looking outside of standard care to experimental treatments.
- 3:37SPEAKER_02: Specifically, the clinical literature is heavily focused on testing whether certain cells, usually taken from cord blood or cord tissue, might offer support to that injured brain.
- 3:46SPEAKER_00: And perhaps ease those downstream movement problems.
- 3:49SPEAKER_00: The scientific interest is really driven by the unique properties these specific cells possess.
- 3:54SPEAKER_02: I saw a specific term repeated constantly in the literature.
- 3:58SPEAKER_00: Mesenchymal stem cells?
- 3:59SPEAKER_02: Yes.
- 4:00SPEAKER_02: Or MSCs for short.
- 4:02SPEAKER_00: Researchers are currently investigating how MSCs extracted from sources like umbilical cord tissue might behave when introduced into the body of a child with cerebral palsy.
- 4:11SPEAKER_02: And when looking at those cord tissue sources, there is another very specific term that appears repeatedly in the data: Wharton's jelly.
- 4:18SPEAKER_00: Yes, that is a key source.
- 4:20SPEAKER_02: From the clinical descriptions, Wharton's jelly is a highly specialized gelatinous layer found deep inside the umbilical cord tissue.
- 4:28SPEAKER_02: And researchers look to it because it is a particularly rich source of these MSCs.
- 4:33SPEAKER_00: It is.
- 4:33SPEAKER_02: To give you some real-world geography for these terms, Cyronacelle is a regenerative medicine center located in Kuala Lumpur.
- 4:40SPEAKER_02: They serve local patients as well as international patients, including families traveling from Australia and the Middle East.
- 4:47SPEAKER_02: According to Cyronicell's own statement, their specific treatments utilize Wharton's jelly-derived mesenchymal stem cells sourced from umbilical cord tissue.
- 4:56SPEAKER_00: That context is helpful to ground this, and we must explicitly separate that statement regarding the center's specific service from the independent published research findings we are analyzing today.
- 5:07SPEAKER_02: Absolutely.
- 5:07SPEAKER_02: The clinical data we are going to unpack comes from external trials and massive reviews.
- 5:11SPEAKER_00: Aaron Powell Which test a wide variety of cell sources and protocols entirely independent of any single clinic.
- 5:17SPEAKER_02: With that separation firmly established, the mechanism behind how these mesenchymal stem cells are theorized to work is genuinely surprising.
- 5:25SPEAKER_00: The mechanism is quite fascinating.
- 5:27SPEAKER_02: Because going into this data, I assume the prevailing theory was that you introduce these cells, they travel up to the brain, and they physically turn into new brain tissue to replace what was damaged.
- 5:37SPEAKER_02: But the authors of a 2021 trial describe a completely different likely main effect.
- 5:43SPEAKER_00: The clinical literature overwhelmingly points away from the idea of cell replacement.
- 5:48SPEAKER_02: So they aren't turning into new brain cells.
- 5:50SPEAKER_00: Researchers theorize that MSCs help primarily by releasing chemical signals and calming inflammation.
- 5:57SPEAKER_00: The theory is that they release a cascade of signals that support the brain's inherent repair mechanisms.
- 6:02SPEAKER_02: Like sort of waking up the body's own tools.
- 6:05SPEAKER_00: In a way.
- 6:22SPEAKER_02: Based on that signaling theory, it's not like we are injecting literal bricks into the body to rebuild a broken wall.
- 6:29SPEAKER_00: No, not bricks.
- 6:30SPEAKER_02: Aaron Powell, it sounds less like injecting bricks and more like dropping a construction foreman onto a highly chaotic work site.
- 6:37SPEAKER_00: Aaron Powell A construction foreman.
- 6:38SPEAKER_02: Aaron Powell Yeah, like the foreman doesn't physically lay the bricks or patch the drywall.
- 6:42SPEAKER_02: Instead, they stand back, shout instructions to calm down the chaos, organize the local repair crew that is already there, and hand out blueprints so the environment can start repairing itself.
- 6:53SPEAKER_00: That analogy perfectly captures the current prevailing theory of MSC signaling.
- 6:57SPEAKER_00: The cells act as managers of the local environment rather than raw building materials.
- 7:02SPEAKER_02: Aaron Powell It is a totally different way of looking at it.
- 7:04SPEAKER_00: Aaron Powell It is.
- 7:05SPEAKER_00: However, a massive caveat must be attached to this entire mechanism.
- 7:10SPEAKER_00: We must firmly note that these ideas regarding chemical signaling and inflammation reduction come predominantly from laboratory settings and animal models.
- 7:18SPEAKER_02: Aaron Powell So not proven in humans yet.
- 7:20SPEAKER_00: Aaron Powell These specific cellular actions remain largely unproven in human children.
- 7:24SPEAKER_00: The theories look highly promising in a petri dish, but a growing human child with a complex neurological injury is an infinitely more complicated environment.
- 7:33SPEAKER_02: Aaron Powell Well, a theory in a lab is only the starting line.
- 7:36SPEAKER_02: Let's look at what the clinical data actually reports when these experimental cells are tested in humans.
- 7:41SPEAKER_02: Starting with the logistics of delivery, a massive 2025 review looked at 30 published reports and 10 registered trials.
- 7:49SPEAKER_00: That is a substantial amount of data.
- 7:51SPEAKER_02: Aaron Powell They found that 75% of the children in these studies received cord tissue MSCs, but how are they actually getting these cells into the body?
- 7:59SPEAKER_00: The review outlines two main delivery routes.
- 8:02SPEAKER_00: About 40% of children received the cells via an intrathecal route.
- 8:06SPEAKER_00: Intrathecal meaning Meaning doctors place the cells directly into the fluid surrounding the spinal cord, and another 38% receive them intravenously, which is administered directly through a vein.
- 8:17SPEAKER_02: Aaron Powell Understanding the delivery method is important, but understanding the trial design is even more critical when looking at the results.
- 8:23SPEAKER_00: Trial design is everything.
- 8:25SPEAKER_02: Let's examine a heavily cited 2021 randomized trial.
- 8:29SPEAKER_02: This involves 72 children, aged between 4 and 14, who were diagnosed with spastic cerebral palsy.
- 8:36SPEAKER_00: And to clarify that clinical term for you, spastic cerebral palsy means the child's muscles are constantly tight and stiff, making movement incredibly difficult.
- 8:44SPEAKER_02: This trial took place across three hospitals in Iran, and the most crucial element of its design is that it utilized a sham procedure.
- 8:52SPEAKER_00: The inclusion of a sham group is the gold standard for this type of research, especially in pediatrics.
- 8:58SPEAKER_02: Aaron Powell For context, a sham procedure is a pretend procedure.
- 9:02SPEAKER_02: In this 2021 trial, chance decided which group a child fell into.
- 9:06SPEAKER_02: The parents did not know if their child received the real cells or the pretend procedure.
- 9:12SPEAKER_00: And crucially, the medical staff judging the child's progress months later also did not know.
- 9:16SPEAKER_02: Aaron Ross Powell This double blinding is so essential because families desperately want to see their child improve.
- 9:23SPEAKER_02: If a parent knows their child received a highly experimental treatment, they might unconsciously rate the child's daily movements as better than they actually are.
- 9:32SPEAKER_00: It happens all the time in trials.
- 9:33SPEAKER_02: Aaron Powell The Sham procedure prevents that pure hope from artificially inflating the data.
- 9:38SPEAKER_02: So looking at the hard data from this carefully controlled trial, what were the findings?
- 9:43SPEAKER_00: Aaron Powell The trial reported that at the 12-month mark, gross motor scores in the group that received the actual cell injections rose about eight points higher than the scores in the sham group.
- 9:53SPEAKER_02: Eight points.
- 9:54SPEAKER_00: In addition to the motor scores, the researchers reported that muscle stiffness fell more significantly in the treated group compared to the control.
- 10:01SPEAKER_02: Aaron Powell An eight-point jump in motor score sounds incredibly substantial for a child navigating spasticity.
- 10:07SPEAKER_00: It is a notable finding, but the authors themselves included a vital limitation in their report.
- 10:12SPEAKER_00: Every single child in the treatment group received one fixed dose of cells.
- 10:16SPEAKER_02: Aaron Powell Meaning they didn't test different amounts.
- 10:19SPEAKER_00: The trial did not test different doses or different routes of administration, meaning we cannot extract any data from the study regarding what the optimal protocol might actually be.
- 10:28SPEAKER_02: Here's where it gets really interesting.
- 10:31SPEAKER_02: If we have a carefully controlled 2021 trial showing an eight-point jump, how do we reconcile that with the massive overarching data reviews?
- 10:41SPEAKER_00: Because they tell a very different story.
- 10:52SPEAKER_00: A huge sample size.
- 10:53SPEAKER_02: When they pulled all that data together, they reported only small average gains.
- 10:58SPEAKER_02: They found an average gain of about one point on a 100-point gross motor function scale at three, six, and twelve months.
- 11:04SPEAKER_00: Just one point.
- 11:06SPEAKER_02: It is also important to note that about 31% of the children in this massive review received the cells through compassionate access.
- 11:13SPEAKER_00: Aaron Ross Powell Meaning outside of the strict parameters of a controlled clinical trial.
- 11:18SPEAKER_02: Aaron Powell How do we jump from eight points in one trial to an average of just one point across the broader data?
- 11:24SPEAKER_00: Aaron Ross Powell The discrepancy you are pointing out highlights the fundamental challenge of researching cerebral palsy.
- 11:30SPEAKER_00: Averages across hundreds of patients often hide massive critical differences between individual children.
- 11:36SPEAKER_02: Aaron Powell Because the injuries are so different.
- 11:38SPEAKER_00: Aaron Powell The condition itself is highly varied.
- 11:40SPEAKER_00: A brain injury can affect a tiny cluster of motor neurons, or it can affect vast networks across the entire brain.
- 11:46SPEAKER_02: Aaron Powell So no two children present the exact same way.
- 11:49SPEAKER_00: Aaron Powell Exactly.
- 11:50SPEAKER_00: Well, the authors of the 2025 review explicitly note that this extreme variability severely limits their ability to draw firm conclusions about how specific subgroups of children might respond.
- 12:02SPEAKER_00: Furthermore, the trial designs across that pool data vary wildly.
- 12:06SPEAKER_02: They aren't comparing apples to apples.
- 12:07SPEAKER_00: They use different cell sources, different preparation methods, different delivery routes, and children with vastly different baseline abilities.
- 12:15SPEAKER_02: To put that one-point average gain into perspective for a family, on a hundred-point clinical scale, a single point might barely register in a child's daily life.
- 12:25SPEAKER_02: It might represent a slightly better posture when sitting, or a fractional change in how a foot lands, rather than a sudden leap in overall mobility.
- 12:33SPEAKER_00: It is a very marginal change.
- 12:35SPEAKER_02: There was also a second 2025 review that focused strictly on core blood trials rather than core tissue.
- 12:41SPEAKER_02: They compared 170 treated children against a comparison group of 171 children.
- 12:46SPEAKER_00: And what did they find?
- 12:47SPEAKER_02: At six months, the treated children scored 1.36 points higher than the comparison group.
- 12:53SPEAKER_02: At 12 months, they scored 1.42 points higher.
- 12:56SPEAKER_02: The one notable correlation the authors found was that higher cell doses were linked to slightly larger gains.
- 13:02SPEAKER_00: This brings us to a frequent pitfall when families are researching this data online.
- 13:07SPEAKER_00: They will often encounter studies that show seemingly massive improvements, but the trial design is fundamentally flawed.
- 13:14SPEAKER_02: A perfect example from the literature is a 2019 retrospective study.
- 13:18SPEAKER_02: This research team looked back at medical records and reported that 48 out of 54 children, given Wharton's jelly cells, showed some level of improvement based on a doctor's rating, with mostly mild adverse events.
- 13:31SPEAKER_00: Which on paper sounds like an overwhelming success rate.
- 13:34SPEAKER_02: Aaron Powell It sounds incredible.
- 13:36SPEAKER_00: The critical flaw in that 2019 study is that it was entirely retrospective and lacked any comparison group.
- 13:42SPEAKER_00: They simply looked at records of children who already received the treatment.
- 13:47SPEAKER_00: Without a control group who received a sham procedure, researchers cannot definitively credit the experimental cells with the observed changes.
- 13:54SPEAKER_02: Aaron Powell Because kids grow and change anyway.
- 13:57SPEAKER_01: A child might have improved due to natural biological development, the ongoing physical therapy they were receiving, or a change in their standard medication.
- 14:05SPEAKER_01: Without a control, that data is purely anecdotal.
- 14:08SPEAKER_01: It is not conclusive clinical evidence.
- 14:11SPEAKER_02: Aaron Powell Given these small average gains of just one or one and a half points reported in the massive 2025 reviews, the data makes it abundantly clear that this experimental therapy is in no way a standalone fix.
- 14:23SPEAKER_02: It does not replace the daily, grueling work of managing the physical symptoms.
- 14:28SPEAKER_02: Which brings us to the absolute anchor of care, traditional rehabilitation.
- 14:33SPEAKER_00: Rehabilitation remains the core foundation for a child with cerebropalsy.
- 14:37SPEAKER_00: It is vital to note that in the trials we discussed, the experimental cells did not replace rehab.
- 14:43SPEAKER_00: They were stacked on top of it.
- 14:44SPEAKER_02: Aaron Powell They were doing both at the same time.
- 14:46SPEAKER_00: In that 2021 trial from Iran, every single child in both the treatment group and the sham group was mandated to attend physical rehab for 75 minutes three times a week.
- 14:56SPEAKER_02: That is a lot of therapy.
- 14:58SPEAKER_00: Aaron Powell The trial was not measuring cells against rehab.
- 15:01SPEAKER_00: It was measuring cells plus rehab against rehab alone.
- 15:05SPEAKER_00: Cell treatment is investigated strictly as a potential add-on, never a replacement for physical and occupational therapy.
- 15:12SPEAKER_02: You know, looking at a 2020 review of standard treatments, um they rated several specific rehab therapies as highly effective based on decades of data.
- 15:22SPEAKER_02: They point to goal-directed training, where a therapist helps the child practice a specific task the child actually wants to achieve, like holding a spoon.
- 15:31SPEAKER_02: Aaron Powell Which is very practical.
- 15:33SPEAKER_02: Yep.
- 15:34SPEAKER_02: They highlight task-specific training, which relies on the intense repetition of a single real-life skill.
- 15:40SPEAKER_02: Strength and fitness training are strongly supported.
- 15:43SPEAKER_02: They also give high marks to constraint-induced movement therapy.
- 15:46SPEAKER_00: That one is particularly interesting.
- 15:48SPEAKER_00: Aaron Powell Yeah.
- 15:49SPEAKER_02: So for you listening, constraint-induced therapy is a fascinating approach where a therapist temporarily puts a cast or a mitt on the child's stronger hand.
- 15:58SPEAKER_00: It sounds restrictive, but there is a logic to it.
- 16:01SPEAKER_02: This physically forces the child to use their weaker hand, forcing the brain to practice and build new neural pathways for that weakened limb.
- 16:09SPEAKER_00: Aaron Powell Because standard therapy is so vital, the actionable advice for any family navigating this landscape is to keep all current medical and therapy plans firmly in place.
- 16:19SPEAKER_00: Nobody should ever alter or stop standard medicines or therapy without direct consultation with their primary physician.
- 16:25SPEAKER_02: You don't want to abandon what works.
- 16:28SPEAKER_00: If a family does decide to pursue an experimental treatment, the literature advises them to ask their physical therapist to record a highly detailed baseline of the child's abilities before any intervention begins.
- 16:40SPEAKER_02: You need a starting point.
- 16:42SPEAKER_00: You need an objective recorded starting line to accurately judge any potential changes later.
- 16:47SPEAKER_02: The sources outline a very specific list of measures parents can track over several months to gauge progress.
- 16:54SPEAKER_02: Families can monitor gross motor skills, watching for minute changes in sitting balance, standing duration, or the ability to take steps.
- 17:02SPEAKER_00: Very specific physical milestones.
- 17:04SPEAKER_02: They can track muscle tone and overall stiffness, relying on their therapist's formal measurements.
- 17:10SPEAKER_02: Daily functional tasks are a crucial metric.
- 17:13SPEAKER_02: Are there subtle improvements in addressing or feeding themselves?
- 17:16SPEAKER_02: Finally, tracking the child's general comfort, their sleep quality, and noting the appearance of any entirely new symptoms provides a holistic view of how their body is reacting.
- 17:26SPEAKER_00: Beyond tracking physical progress, the literature strongly advises families to request comprehensive, written records from any clinic providing experimental treatments.
- 17:35SPEAKER_02: Like a paper trail.
- 17:37SPEAKER_00: Families must advocate for documents that detail the specific cell source used, the exact cell count or dose administered, and the specific route of delivery.
- 17:46SPEAKER_02: Having those exact details on paper is so important because, as we saw in the 2025 review, trials vary wildly.
- 17:54SPEAKER_02: A child's primary care doctor at home cannot accurately monitor the child's safety or weigh the clinical evidence unless they know exactly what was administered.
- 18:01SPEAKER_00: Trevor Burrus, Jr.
- 18:01SPEAKER_00: It is basic medical safety.
- 18:03SPEAKER_02: Aaron Powell And safety monitoring is paramount because there are still significant short-term risks and massive long-term unknowns documented in this young field.
- 18:12SPEAKER_02: Looking at the data, what short-term reactions are researchers reporting?
- 18:16SPEAKER_00: Aaron Ross Powell The primary risks reported in the literature center on short-term reactions immediately following the administration of the cells.
- 18:23SPEAKER_00: In the 2021 sham-controlled trial, the reported reactions included fever, headache, back pain, generalized fussiness, and vomiting.
- 18:32SPEAKER_02: Aaron Powell That sounds fairly intense for a child.
- 18:34SPEAKER_00: Aaron Powell The researchers noted these symptoms typically appeared within 24 hours of the procedure and reportedly resolved, with no serious adverse events noted during their specific follow-up window.
- 18:45SPEAKER_00: Aaron Powell Okay.
- 18:45SPEAKER_02: So they faded quickly.
- 18:47SPEAKER_00: However, looking back at the 2019 retrospective records, the data shows that one child's preexisting epilepsy actually worsened following the injections and their treatment was permanently stopped.
- 18:58SPEAKER_02: Aaron Powell Those are the documented reactions in the days and weeks following a procedure, but what about the long game?
- 19:04SPEAKER_02: What does the clinical data tell us about a child's neurological and physical trajectory five, ten, or fifteen years after receiving these experimental cells?
- 19:12SPEAKER_00: Aaron Powell The clinical data tells us almost nothing about the long-term picture, which is a stark reality that families must carefully weigh.
- 19:20SPEAKER_00: Nothing.
- 19:21SPEAKER_00: The 2025 review of cell trials explicitly states that there are currently no published late-stage trials available.
- 19:28SPEAKER_00: The pooled results from these massive reviews only track patient progress up to 12 months post-treatment.
- 19:34SPEAKER_02: So we simply don't know what happens in year two or three.
- 19:36SPEAKER_00: Any potential longer-term effects, whether those are delayed positive gains or unforeseen negative complications, remain entirely unclear.
- 19:44SPEAKER_00: The field simply hasn't existed long enough with enough controlled tracking to answer those questions.
- 19:50SPEAKER_00: The most critical variables, the optimal dose, the safest route, and the most effective cell source, remain unknown.
- 19:56SPEAKER_02: There was also a major hurdle in how researchers even measure success, isn't there?
- 20:01SPEAKER_02: Going back to the 2021 trial, the authors themselves issued a pretty significant caution about their own data gathering.
- 20:07SPEAKER_02: They noted that the scale they use to rate the children's muscle stiffness suffers from low interratar reliability.
- 20:14SPEAKER_00: Aaron Powell The issue of measurement subjectivity is a persistent hurdle in neurological trials.
- 20:19SPEAKER_02: Aaron Powell To put that simply for you listening, low interratar reliability means the scoring system is highly subjective.
- 20:26SPEAKER_02: It means two different doctors could watch the exact same child walk across a room, examine their muscle stiffness, and come up with two completely different scores on that scale.
- 20:35SPEAKER_00: Aaron Powell Because they are judging it with their own eyes.
- 20:37SPEAKER_02: Aaron Powell When the measurement tool itself is subjective, it introduces a layer of static into the data that makes it incredibly difficult for researchers to firmly prove a treatment's effectiveness.
- 20:46SPEAKER_00: Aaron Powell This inherent subjectivity is precisely why the authors of the 2025 reviews are calling for much larger, better design trials that utilize objective markers and openly share their raw data.
- 20:58SPEAKER_00: For anyone weighing the option of stem cell therapy, the literature suggests asking the provider for published papers that describe their specific cell product and inquiring about the exact regulatory status of that product in their jurisdiction.
- 21:12SPEAKER_02: So, what does this all mean?
- 21:14SPEAKER_02: We have sifted through clinical trials, massive data reviews, and the mechanics of standard care.
- 21:21SPEAKER_02: The grounded clinical truth we extract from these sources is very clear.
- 21:26SPEAKER_02: Researchers currently know of no cure for a cerebral palsy.
- 21:29SPEAKER_00: That is the medical reality.
- 21:31SPEAKER_02: This therapy remains strictly experimental and is not a replacement for standard medical care.
- 21:37SPEAKER_02: When it comes to the logistics of seeking treatment, the data shows that costs depend heavily on variables like the specific cell type, the required dose, the delivery route, and the necessary follow-up care.
- 21:48SPEAKER_02: For instance, CironaCell states that their treatment plans are determined following a personal medical review rather than offering a fixed package price for every patient.
- 21:58SPEAKER_00: Which aligns with how varied the condition is.
- 22:01SPEAKER_02: And above all else, the data proves that standard rehabilitation, the grueling daily physical therapy, the goal-directed training, remains the absolute unshakable foundation of a child's care.
- 22:12SPEAKER_02: Experimental cells are only ever investigated in the literature as a potential add-on to support that vital rehab work.
- 22:19SPEAKER_00: As we conclude our analysis of this data, I want to leave you with a final thought to mull over.
- 22:24SPEAKER_00: One that ties directly back to the mechanisms we explored earlier.
- 22:27SPEAKER_02: Let's hear it.
- 22:29SPEAKER_00: If the prevailing clinical theory holds true that the real power of these mesenchymal stem cells lies purely in the chemical signals they release rather than the physical cells themselves, could the future of this medicine involve abandoning live cell injections entirely?
- 22:43SPEAKER_02: Aaron Powell Abandoning the cells themselves.
- 22:45SPEAKER_00: Might the field eventually evolve to simply isolate those chemical signals in a laboratory and deliver those isolated signals directly to the injured brain, bypassing the immense complexities and risks of injecting live cells altogether?
- 22:59SPEAKER_02: That is a profound question for the future of regenerative medicine and exactly the kind of critical thinking this complex research requires.
- 23:08SPEAKER_02: Thank you for joining us on this deep dive.
- 23:10SPEAKER_02: We hope this rigorous exploration of the clinical data has cut through the noise and armed you with the clear, evidence based insights you need.